Modeling receptor-mediated processes with dioxin: implications for pharmacokinetics and risk assessment

Area of Science:

• Environmental Toxicology
• Molecular Carcinogenesis
• Pharmacokinetics

Background:

• Dioxin (2,3,7,8-tetrachlorodibenzo-p-dioxin; TCDD) is a toxic pollutant linked to liver and other tumors.
• TCDD toxicity and carcinogenicity are mediated by interaction with the Ah receptor, altering gene expression.
• The U.S. EPA is developing new risk assessment strategies for receptor-mediated toxicants like dioxin.

Purpose of the Study:

• To describe a receptor-mediated physiologically based pharmacokinetic (PB-PK) model for dioxin.
• To examine dioxin's tissue distribution and enzyme-inducing properties using this model.
• To discuss the utility of PB-PK models in biologically motivated risk assessments for dioxin.

Main Methods:

• Development of a PB-PK model incorporating Ah receptor-dioxin-DNA interactions.
• Simulation of dioxin tissue disposition and induction of hepatic proteins (cytochrome P4501A2 and P4501A1).
• Correlation of tumor promotion with predicted enzyme induction levels.

Main Results:

• The model simulates dioxin's distribution and induction of specific hepatic proteins.
• Tumor promotion showed a stronger correlation with predicted P4501A1 induction than with dioxin-binding proteins.
• Enhanced protein induction is not considered causally linked to tumor formation.

Conclusions:

• PB-PK models are valuable for understanding dioxin's mechanism of action.
• These models can determine target tissue doses and gene product levels for risk assessment.
• Further research can link gene products to cellular events in dioxin-induced tumor promotion.